Clozic 表现出可逆的抗增殖作用，可用于作为潜在抗关节炎剂的研究。

Clozic exhibits reversible anti-proliferative effects and can be used in studies about serving as a potential anti-arthritic agent.

Clozic (>50 μM) dose-dependently decreases the amount of matrix protein synthesized by RHMC cell cultures. Clozic dose-dependently inhibits RHMC cell culture growth. Clozic (500 μM) does not affect Lactate dehydrogenase levels[1].

22494-47-9

C17H17ClO3

304.77

氯丁扎利;ICI 55897

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years